Ke-Qin Hu

picture of Ke-Qin  Hu

Professor of Clinical Medicine
School of Medicine
Director, Hepatology Services, H.H. Chao Comprehensive Digestive Disease Center
School of Medicine

M.S., Tongji Medical University, 1985, Infectious Diseases and Immunology
M.D., Tongji Medical University, 1982

Phone: (888) 717-4463
Fax: (714) 456-3823
Email: kqhu@uci.edu

University of California, Irvine
101 The City Dr S
Bldg 56
Orange, CA 92868
Research Interests
Natural history and new treatments of viral hepatitis B and C; natural history and chemoprevention of primary liver cancer
Academic Distinctions
Research Support Award, Loma Linda University School of Medicine
Research Abstract
Dr. Ke-Qin Hu is the Director of Hepatology Services and Associate Professor of Clinical Medicine at UCI School of Medicine. Dr. Hu received his medical education and training in Tongji Medical University, China. He become Board Certified in Internal Medicine in US after his residency at Huntington Memorial Hospital, Pasadena, and completed a fellowship in Hepatology at the USC Liver Unit. Dr. Hu has a long-standing research interest in both basic and clinical research of viral hepatitis B and C, and primary liver cancer. Dr. Hu’s current clinical research focuses on understanding how hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is associated with fatty infiltrates in the liver and disease progression, and how viral hepatitis B and C are associated with liver cancer. As an active clinical investigator, Dr. Hu participates in several important clinical trials that tests new treatments for hepatitis B and C. Currently, his laboratory focuses on searching new chemoprevention of liver cancer. Dr. Hu has co-authored more than 100 research papers, book chapters, and review articles, including publications in Proc. Natl. Acad. Sci. USA, Journal of Clinical Investigation, and Hepatology. Dr. Hu serves as an associate editor for several medical journals.
Publications
Abstracts
1. Hu K-Q, Yu CH, Villamil FG, et al. Comparison of HCV cDNA polymerase chain reaction (PCR) using primer from the 5'-non-coding and nonstructural regions of HCV genome. Hepatology 1991; 14:207A.
2. Hu K-Q, Yu CH, Vierling JM. Detection of circulating HCV RNA by slot hybridization using cDNA probe from the 5'-non-coding region. Hepatology 1991; 14:118A. Presented at the Third International Symposium on Hepatitis C, Stasbourg, France, September, 1991 and the 42nd annual meeting of the American Association for the Study of Liver Diseases, Chicago, IL, November, 1991.
3. Hu K-Q, Yu CH, Vierling JM. Cytokine production in mice developing non-suppurative destructive cholangitis (NSDC) during chronic graft-vs.-host disease (CGVHD). Hepatology 1991; 14:166A.
4. Hu K-Q, Yu CH, Vierling JM. The HBV X gene product induces the expression in vitro of intercellular adhesion molecule (ICAM-1). Hepatology 1991; 14:124A. Presented at the Plenary Session of the International Meeting on Hepatitis B Virus, Paris, France, September, 1991 and the 42nd annual meeting of the American Association for the Study of Liver Diseases (Plenary Session), Chicago, IL, November, 1991.
5. Hu K-Q, Yu CH, Vierling JM. Enhanced transcription of interferon gamma, but not alpha receptors by hepatitis B virus X protein. Presented at the "International HBV Meeting, 1992.", La Jolla, CA, August, 1992.
6. Hu K-Q, Yu C-H and Vierling JM. A simple one step polymerase chain reaction (PCR) method for detection of hepatitis C virus (HCV) RNA. Hepatology 16: 205A, 1992.
7. Hu K-Q, Yu C-H and Vierling JM. The role of T cell subsets in the pathogenesis of nonsuppurative destructive cholangitis (NSDC) in murine chronic graft-vs.-host disease (CGVHD). Hepatology 16:92A, 1992. Presented at the 43rd annual meeting of the American Association for the Study of Liver Diseases (Presidential Plenary Session), Chicago, IL. November 2, 1992.
8.Hu K-Q, Yu C-H and Vierling JM. The X protein (pX) of the hepatitis B virus (HBV) increases transcription of interferon-? but not interferon-? receptors. Hepatology 16:102A, 1992. Presented at the 43rd annual meeting of the American Association for the Study of Liver Diseases, Chicago, IL, November 2, 1992.
9. Villamil FG, Yu C-H Hu K-Q, Makowka L, Podesta L, Sher L, Howard T, Memsic L, Hoffman A, Petrovic L, Aziz H and Vierling JM. Alfa 2b-Interferon (?2b-IFN) therapy of hepatitis C following liver transplantation (LT). Hepatology 16:48A, 1992. Presented at the 43rd annual meeting of the American Association for the Study of Liver Diseases, Chicago, IL, November 2, 1992.
10. Villamil FG, Yu C-H, Hu K-Q, Lee S, Makowka L, Podesta L, Sher L, Memsic L, Hoffman A, Breda M, Rojter S, Vierling JM: Prevalence of circulating HCV RNA in adult patients with fulminant hepatic failure. Presented at the Fourth International Symposium on HCV, Tokyo, Japan. May 7-9, 1993.
11.Hu K-Q, Yu C-H, Lee S, Villamil FG, Vierling JM: Simultaneous detection of both HBV DNA and HCV RNA by a combined one-step PCR technique. Presented at the Fourth International Symposium on HCV, Tokyo, Japan. May 7-9, 1993.
12. Villamil FG, Yu C-H, Hu K-Q, Lee S, Makowka L, Podesta L, Sher L, Memsic L, Hoffman A, Breda M, Rojter S, Vierling JM: Detection of hepatitis C virus (HCV) by RNA polymerase chain reaction (PCR) in fulminant hepatic failure (FHF). Presented at the American Gastrointestinal Association/American Association for the Study of Liver Diseases, Boston, MA, May 16-19, 1993.
13. Freilich BL, Hu K-Q, Yu C-H, Vierling JM: Hepatic inflammatory cell infiltrates during murine chronic graft-vs.-host disease (CGVHD): are the cells of donor or host origin? Presented at the annual meeting of the American Gastroenterology Association, New Orleans, LA, May 15-18, 1994. Gastroenterology 1994; 106:A894.
14. Freilich BL, Hu K-Q, Yu C-H, Vierling JM: Propagation of hepatic T cells that react with biliary epithelial cells (BEC) in a murine model of chronic graft-vs. host disease (CGVHD). Presented at the annual meeting of the American Gastroenterology Association, New Orleans, LA, May 15-18, 1994. Gastroenterology 1994; 106:A894.
15. Villamil FG, Petrovic L, Hu K-Q, Sher L, Podesta L, Woolf GM, Makowka L, Vierling JM: Efficacy and safety of alfa-2b interferon therapy for hepatitis C after liver transplant. Presented at the biennial meeting of the International Association for the Study of the Liver, Cancun, Mexico, May 19-23, 1994.
16. Hu K-Q, Yu CH, Vierling JM. Variable hepatitis B virus X protein (pX) transactivation of the intercellular adhesion molecule-1 (ICAM-1) gene in different human cell lines. Hepatology 1994; 20:305A.
17. Hu K-Q, Yu CH, Vierling JM. Overexpression of hepatitis C virus envelope protein in transformed human hepatoma cells. Hepatology 1994; 20: 231A.
18. Freilich BF, Nyguen T, Hu K-Q, Yu CH, Vierling JM. Immunoisolation of biliary epithelial cells (BEC) from the liver of mice bile duct ligation. Hepatology 1994; 29:146A.
19. Yu CH, Hu K-Q, Golaman DE, Villamil FG, Camacho K, Rojter S, Vierling JM. Prevalence of hepatitis G virus (HGV) RNA in patients with chronic liver diseases. Hepatology 1996; 24: 420A.
20. Yu CH, Hu K-Q, Goldman DE, Petrovic L, Villamil FG, Camacho K, Rojiter S, Woolf G, et al. Hepatitis G virus (HGV) RNA in patients undergoing liver transplantation (LT). Hepatology 1996; 24:420A.
21. Verling JM, Yu CH, Hu K-Q, Hreha GI, Jefferson, DM. SV40 transformation of BALB/c mouse intrahepatic biliary epithelial cells (BEC). Hepatology 1997; 24:398A.
22. Hu K-Q, Tong MJ. The long-term clinical outcomes of patients with HCV-related compensated cirrhosis and history of parenteral exposure. Gastroenterology 1998; 114: A1258-A1259.
23. Yu CH, Hu K-Q, Vierling JM. A severe combined immunodeficiency (SCID) mouse model with stable HBV replication after implantation of a human hepatoma cell line expressing HBV. Hepatology 1998; 28:215A.
24. Hu K-Q, Bonacini M, Lindsay KL, Redeker AG. The clinical profile of chronic hepatitis C in a major county medical center outpatient setting in the United States. Submitted to 6th International Symposium on Hepatitis C & related viruses, 1999.
25. Hillebrand DJ, Bush D, Concepcion W, Ojogho O, Hu K-Q, Radovich, et al. Local control of hepatocellular carcinoma with proton beam therapy followed by curative liver tramsplantation. Am J Gactroenterol 2000; 95:2578.
26. Hu K-Q, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Gastroenterology 2000; 118: A 1450.
27. Hu K-Q, Yang H, Lin Y-C, Patel S, Redeker AG. Clinical profile of chronic hepatitis B in comparison with chronic hepatitis C in a major county medical center outpatient setting in the United States. Hepatology 2000; 32:576A.
28. Hu K-Q, Lin Y-C, Yang H, McCracken J, Tyler D, Patel S, Hillebrand D, Ojogho O, Concepcion W, Griffin R. Clinical profile of chronic hepatitis C in US veterans in comparison with non-veterans. Hepatology 2000; 32: 280A.
29. Hillebrand DJ, Bush DA, Concepcion W, Ojogho O, Hu K-Q, Radovich P, Slater JD, Slater JA. Proton beam therapy for hepatocellular carcinoma: Analysis of the first twenty-two patients. Hepatology 2000; 32:282A.
30. Hillebrand DJ, Bush DA, Concepcion W, Hu K-Q, Ojogho O, Slater JD, Slater JA. Local control of hepatocellular carcinoma with proton beam therapy followed by curative liver transplantation. Am J Gastroenterol 2000; 95: 2578A.
31. Kerekes E, Hillebrand D, Baron P, Hu K-Q, Ojogho OK, Concepcion W. Warm ischemia time does not affect development of severe recurrent hepatitis C following liver transplantation. A J Transplant 2001; 1 (Suppl 1): 206A.
32. Hill K, Hillebrand D, Cheek G, Baron P, Hu K-Q, Concepcion W. Methylene blue infusion transiently improves PaO2 in severe hepatopulmonary syndrome while awaiting liver transplantation. A J Gastroenterol 2001; in press.
33. Baron P, Hillebrand DJ, Rhambharose JA, Hu K-Q, Ojogho K, Berger K, et al. Scelromyxedema and polymyonecrosis following liver transplantation. Am J Transplantation 2001:1(suppl 1) 20421A.
34. Hu K-Q, Esrailian E, Runyon B, Thompson K, Chase R, Abdelhalin F, et al. Clinical implication of hepatic steatosis in patients with chronic hepatitis C. Hepatology 2001; 34:220A.
35. Hu, K-Q, Hu Y-W, McCracken J, Balaskas E, Tyler D, Pappas J, et al. Frequency and clinical relevance of HCV genotype 6 and non-6 in veterans vs. non-veterans by a semiautomated mispair extension analysis (S-PSMEA) and direct sequencing. Hepatology 2001; 34:571A.
36. Hu K-Q, McCracken J, Mineyama Y, Yu C-H, Hillebrand D. Characterization of inhibited growth of cyclooxygenase-2 (COX-2) expressing human hepatoma cells by a selective COX-2 inhibitor (NS-398). Hepatology 2001; 34: 388A.
37. Hu K-Q, Hill K, Abdelhalim F, Hillebrand DJ, Chen CS. A pilot study of celecoxib tolerability in patients with chronic liver disease (CLD) and stage III-IV hepatocellular carcinoma (HCC). Gastroenterology 2002; 122:659-A.
38. Hu K-Q, Yu C-H. Comparison of celecoxib with NS-398, sulindac, and R-flurbiprofen on suppression of human hepatocellular carcinoma (HCC) cell proliferation. Hepatology 2002; 36:704A.
39. Hu K-Q, Elhazin B, Hillebrand DJ, Abdelhalim F, Kyulo N.Clinical significance of elevated alpha fetoprotein (AFP) in patients with chronic hepatitis C. Hepatology 2002; 36: 544A.
40. Hu K-Q, Esrailian E, Thompson K, Chase R, Abdelhalin F, Kyulo N, et al. Hepatic Steatosis Is Associated with Disease Progression of Chronic Hepatitis C: A Large Cohort Study in the United States. Hepatology 2002; 36:349A.
41. Hu K-Q, Cheung R, Rossi S, Bini EJ, Jeffers L, Wright T. Risk Factors for Hepatitis C Virus (HCV) Infection in US Veterans: A Large VA Multicenter Study Hepatology 2002; 562A.
42. Hu K-Q, Yu C-H, Hasan M. In vitro and in vivo inhibition of proliferation of human hepatocellular carcinoma (HCC) cells by celecoxib. Hepatology, 2002; 36: 391A.
43. Hillebrand HJ, Bush DA, Radovich P, Hu K-Q, Baron P, Ojogho O, et al. Successful management of hepatocellular carcinoma (HCC) in patients listed for liver transplantation with proton beam therapy while on the waiting list. Hepatology 2002; 36: 394A.
44. Hillebrand HJ, Hill K, Hu K-Q. Safe, rapid and effective resolution of episodic type C hepatic encephalopathy with charcoal-based hemodiabsorption utilizing the liver dialysis unit. Hepatology 2002; 36:172A.
45. Hillebrand HJ, Hill K, Hu K-Q. Cottrell A, Teichman. Formal heparin anticoagulation protocol improves safety of charcoal-based liver assist treatment. ASAIO 2002; 48:186.
46. Srikureja W, Kyulo NL, Runyon BA, Hu K-Q. MELD score is a better prognostic model than Child-Turcotte-Pugh score or discriminant function score in patients with alcoholic hepatitis. Gastoenterology 2003; 124:A704.
47. Esrailian E, Pantangco ER, Kyulo N, Hu K-Q, Runyon BA. Octreotide/midodrine therapy significantly improves survival in type 1 hepatorenal syndrome: analysis of 53 treated patients & 21 controls. Gastoenterology 2003; 124:A718.
48. Hu K-Q, Cheung R, Currie S, et al. Hepatic steatosis in patients with chronic hepatitis C: A multicenter study of US veterans. Hepatology 2003; 38 (Suppl. 1):445A.
49. Bini EJ, Brau N, Currie S, Shen H, Anand B, Hu K-Q, et al. Epidemiology of hepatitis C infection and eligibility for antiviral therapy among U.S. veterans. Hepatology 2003; 38 (Suppl. 1):452A.
50. Brau N, Bini EJ, Currie S, Shen H, Anand B, Hu K-Q, et al. Treatment of chronic hepatitis C with interferon alfa-2b and ribavirin in the community-based practice. A prospective study of 813 U.S. veterans. Hepatology 2003; 38 (Suppl. 1):643A.
51. Hillebrand DJ, Bush DA, Hu K-Q, Radovich P, Slater JD, Slater JA, et al. Proton therapy for hepatocellular carcinoma : largest reported US experience to date. Hepatology 2003; 38 (Suppl. 1):756A.
52. Cheung R, Currie S, Shen H, Hu K-Q, Ho SB, Jeffers L, et al. No differences in Treatment Response to HCV in Mexican Americans. Gastroenterology 2004; 126 (suppl. 2): A698.
53. Hu K-Q, Lee S, Kyulo N, et al. A comparative study of the natural history of chronic hepatitis C in patients with normal renal function vs. chronic renal failure. Gastroenterology 2004; 126 (suppl. 2): A742.
54. Hu K-Q, Kyulo N, Hillebrand DJ et al. Factors associated with advanced hepatic fibrosis in patients with chronic hepatitis C. Gastroenterology 2004; 126 (suppl. 2): A745.
55. Xia V, Liu L, Tran A, Hu K-Q, Kyulo N, Hiatt J, Busuttil R and Steadman R. Intraoperative potassium disturbances in pediatric patients undergoing orthotopic liver transplantation-a retrospective study of consecutive 219 cases in a single center. Anesthesiology 2004; 101:A1436.
56. Wong PY, Kyulo NL, Imagawa DK, Hoefs J, Hu K-Q. Clinical presentation and stage of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian-Americans. Gastroenterol 2005; 120 (suppl. 2): A-758.
57. Hu K-Q, Kyulo NL, Anton-Culver H, Taylor TH. Epidemiologic Trends of Hepatocellular Carcinoma (HCC) in California and Orange County between 1991 and 2000. Gastroenterol 2005; 120 (suppl. 2): A-758.
58. Cui W, Yu C-H, Tang Z, Hu K-Q. In Vivo and In Vitro Effect and Mechanisms of Cyclooxygenase-2 (COX-2)-independent Growth Inhibition of Human Hepatocellular Carcinoma (HCC) Cells by Celecoxib. Hepatology 2005; 42 (Suppl.): 302A.
59. Lah J, Cui W, Hu K-Q. Inhibitory effects and mechanisms of silibinin on growth of human hepatoma cell lines. Hepatology 2005; 42 (Suppl.): 309A.
60. Kelly N, Tran A, Du B, Hu K-Q, Steadman R, and Xia V. Intraoperative potassium disturbances during primary orthotopic liver transplantation in patients age 50 and older-- a single center retrospective study of 406 cases. Liver Transpl 2005; 11:C39.
61. Hoang K, Kyulo NL, Xia, V, Hoefs J, Bui L, Wu M, Hu K-Q. Different clinical presentation and treatment response of chronic hepatitis C in Asian-Americans versus non- Asian-Americans. Hepatology 2005; 42 (Suppl.): 676A.
62. Du B, Steadman R, Hu K-Q, Xia V. Prereperfusion hyperkalemia and risk factor analysis in 1134 cases of adult liver transplantation. Anesth & Analg 2006: S-58.
63. Mellen JS, Kyulo NL, Xia VW, Hoefs J, Imagawa D, Hu K-Q. The Natural History of Chronic Hepatitis B Virus (HBV) Infection in Asian Americans: A Retrospective Single Center Study. Gastoenterology 2006; 130: A-850.
64. Fond A, Du B, Hu K-Q and Xia V. Is hyponatremia associated with increased perioperative risks in the MELD era? Liver Transpl 2006; 12: C158.
65. Cui W and Hu K-Q. In Vivo Effects and Mechanisms of Silibinin on Human Hepatoma (HuH7) Xenografts in Nude Mice. 2006 AASLD meeting, Boston, accepted for poster presentation.
66. Xia V, Ghobrial RM, Neelakanta G, Hu K-Q, Busuttil RW and Steadman RH. Are extended criteria donors associated with higher potassium levels in adult liver transplantation? Anesthesiology 2006: A42.
67. Chen SL, Cui W and Hu K-Q. Effects and Mechanisms of Pentoxifylline on a HepG2 Steatosis Model. 2006 AASLD meeting, Boston, accepted for poster presentation.
68. Freilich B, Hu K-Q, Jacobson I, Brown R, McCone J, Black M, Albert C, Dragutsky M, Griffel L, Brass C. Prospective Analysis of Sustained Virologic Response (SVR) to Peg-interferon (PEG IFN) Alfa-2b and Ribavirin Treatment in Asian and Hispanic Patients with Chronic Hepatitis C: Results from the WIN-R Trial. 2006 AASLD meeting, Boston, accepted for poster presentation.
69. Xia V, Hu K-Q, Hiatt HR, Busuttil RW, and Steadman RH. Predictors of postreperfusion hyperkalemia in adult liver transplantation: the impact of donors. Liver Transpl 2007: S353.
70. Hu K-Q, Schiff ER, Kowdley KV, Min AD, Shiffman ML, Lee WM, Goodman Z, Dau L, Peschell KJ, Flaherty J. Histologic evidence of active liver injury in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B and normal or minimally elevated serum ALT presented in 2008 DDW.
71. Pan CQ, Hu K-Q, Ding C, Cheung E. Prevalence of HCV and Risk of HCV Acquisition in Hepatitis C Screening Programs in Asian community in New York City. Am J Gastroenterology, 103(S1):S138, 2008.
72. Xia V, Obaidi R, Park C, Hu K-Q, and Steadman R. A novel insulin regiment that targets patients with risk factors of hyperkalemia during liver transplantation. Liver Transpl 2008:S22.
73. Pan C, Hu K-Q. Excellent Treatment Response to Tenofovir (TDF) Monotherapy in Chronic Hepatitis B (CHB) Patients with Prior Suboptimal Response to Entecavir (ETV) Monotherapy. Hepatology 2008; 48 (suppl):725A.
74. McCone J, Hu K-Q, McHutchison JG, ML Shiffman, J King, SK Herrine, et al. SVR in African American Patients: Results of the IDEAL Study (Individualized Dosing Efficacy versus Flat Dosing to Assess OptimaL Pegylated Interferon Therapy). Hepatology 2008; 48 (suppl):430A.
75. Nyberg L, Shiffman ML, Bonilla H, Hu K-Q, Morgan T, Levine R, et al. Predictability of response is important in care of CHC Patients: results from the IDEAL Study (Individualized Dosing Efficacy versus Flat Dosing to Assess OptimaL Pegylated Interferon Therapy) Phase IIIB study. Hepatology 2008; 48 (suppl):1134A.
76. Park C, Yersiz H, Huh M, Steadman R, Chen R, Hu K-Q, Hong J, Busuttil R, and Xia V. Severe Intraoperative Glucose Variability and Extended Criteria Donor: Association with Surgical Re-intervention for Hemorrhage in Liver Transplantation. Liver Transplantation 2009; 15 (Suppl 1):S234.
77. Pan C , Zeng Z, Hu K-Q. Clinical Features of Chronic Hepatitis B (CHB) in Treatment Naïve Asian Patients with Positive HBeAg and Co –existing Precore and/or Basal Core Promoter (PC/BCP) Mutations. Gastroenterology, 136(5-S1):P327, 2009.
78. Kim WR, Kim KE, Tarrell R, Chase D, Hu K-Q, Tsai NC. Successful Linkage to Care following Screening for Hepatitis B Virus Infection in the HepBLink Program. Submitted to AASLD meeting, Boston, Nov. 2009.
79. Harrison SA, Rossaro L, Hu K-Q, Patel K, Tillmann H, Dhaliwal S, Torres DM, Koury K, Goteti VS, Noviello S, Albrecht JK, McHutchison JG, Sulkowski MS. Relationship of the Use of Statins and Elevated Low-Density Lipoprotein (LDL) or Total Cholesterol (TC) to Virologic Response in Patients Treated for Hepatitis C Virus (HCV) in the IDEAL Study. Submitted to AASLD meeting, Boston, Nov. 2009.
80. Clawges M, Pan C, Xia VW, Hu K-Q. Regular ALT Monitoring Identifies Cases with Active Chronic Hepatitis B (CHB) in Asian Americans with Chronic Hepatitis B Virus (HBV) Infection. Submitted to AASLD meeting, Boston, Nov. 2009.
81. Gao S-Y, Hu K-Q, Guo W, Ding H-F, Zhao Z-G, Qi J-Y. Outcomes in 161 patients with decompensated hepatitis B. Hepatol International 2010; 4:99.
82. Tong MJ, Chang T-J, Wu S-S, Han K-H, Yoon SK, Pan C, Kowdley K, Hu K-Q, Goodman Z, et al. Histologic improvement in Asian patients with HBeAg(+) and HBeAg(-) chronic hepatitis B after long-term treatment with entecavir: results from ETV-022, -027, and -901 studies. 2010 Digestive Disease Week, New Orleans. Abstr. #633.
83. Abbasi A, Xia VX, Hu K-Q. Clinical presentation and the risks for a higher incidence of cirrhosis and/or hepatic decompensation in elderly patients with chronic liver diseases (CLD). 2010 Digestive Disease Week, New Orleans. Abstr. #S1917.
84. Abbasi A, C Pan, Xia VX, Hu K-Q. Clinical presentation of chronic hepatitis B (CHB) and C (CHC)and the risks for cirrhosis and/or hepatic decompensation, and hepatocellular carcinoma (HCC) in Asian Americans. 2010 Digestive Disease Week, New Orleans. Abstr. #T1972.
85. Memarzadeh M, Cheng R, Chen J, Hu K-Q, Steadman RH, Busuttil RW, and Xia V. Red Blood Cell Storage Age and Potassium Concentrations in Adult Liver Transplantation Liver Transplantation 2010:A181.
86. Chen J, Singhapricha T, Hu K-Q, Steadman RH, Busuttil RW, and Xia V. Post-liver transplant acute kidney injury by the RIFLE criteria in patients with normal preoperative renal function. Liver Transplantation 2010:A345.
87. Abbasi A, Xia V, and Hu K-Q. The Differences of Clinical Presentation of Chronic Hepatitis C (CHC) and the Factors Associated with Steatosis in Asian Americans (AsAs) with Non-Asian Americans (Non-AsAs). Hepatology 2010; 52 (Suppl):1223A.
88. Hsu Y-N, Pan C, Abbasi A, Xia VW, and Hu K-Q. Clinical Presentation and Assessment of Chronic Hepatitis B Disease Phases Using Conventional Vs. Modified ALT Criteria in Asian Americans. Hepatology 2010; 52 (Suppl):999A.
89. Sulkowski MS, Harrison SA, Rossaro L, Hu K-Q, et al. Impaired Fasting Glucose Is Associated with Lower Rates of Sustained Virologic Response (SVR) in Patients With Genotype 1 Chronic Hepatitis C (CHC): Retrospective Analysis of the IDEAL study. Hepatology 2010; 52 (Suppl):712A.
90. Pan C, Tong MJ, Kowdley KV, Hu K-Q, Chang T-T, et al. Long-term Entecavir Treatment for Up to 5 Years in Asians With HBeAg-positive Chronic Hepatitis B: Results From ETV-022 and -901. Hepatology 2010; 52 (Suppl):557A.
91. Gish R, Tsai N, Pan C, Kowdley K, Hu K-Q, Lai CL, et al. Efficacy and Safety of Entecavir in Nucleos(t)ide Naive Asians with HBeAg Positive and Negative Chronic Hepatitis B: Results from Studies ETV-022/027. Hepatology 2010; 52 (Suppl):561A.
92. Lai C-L, Yoon S-K, Wu S-S, Han K-H, Pan C, Kowdley, Hu K-Q, Lee SS, et al. Long-term virologic suppression, resistance and histologic improvement in nucleos(t)de-naïve Asian chronic hepatitis B patients treated with entecavir in studies ETV-22/-027/-901. Heptol International 2011; 5:119A.
93. Cui W and Hu K-Q. The Synergistic Effects and the Mechanisms of Flavokawain A (FA) and Silibinin (S) on Growth of Human Hepatoma Cell. Hepatology 2011; 54 (Suppl): 2018A.
94. Abbasi A, Nguyen TV, Shen D, Tran D, Banh K, and Hu K-Q. The Prevalence and Presentation of Hepatitis B and C Virus (HBV and HCV) Serologic Tests in Vietnamese Americans (VAs) Assessed by a Serial Community Screening for Both HBV and HCV. Hepatology 2011; 54 (Suppl): 1097A.
95. Yang Y, Lu Y, Wang C, JQu J, Chang X, An L, Hu K-Q. Efficacy of Combined Sorafenib and Cryotherapy for Advanced Hepatocellular Carcinoma (HCC): A Single Center Randomized Clinical Study. Hepatology 2011; 54 (Suppl): 2145.
96. Lee H, Hu K-Q, Tonthat S. HBV Treatment Induced HBsAg Seroconversion to Anti-HBs in 9 Asian-American Patients: Experience in a Community Clinic. Hepatology 2011; 54 (Suppl): 1420A.
97. Hu K-Q. Racial Difference in Response to Interferon/Ribavirin Therapy. Hepatol International 2012; 6:164 (TCS21-01).
98. Hu K-Q, Bognar FA, Thompson S, Pedicone L, Wahl J, Lim SG. Boceprevir (BOC) Plus Peginterferon alfa-2b/ribavirin (PR) in the Treatment of Chronic Hepatitis C Virus Genotype-1 (HCV-G1) Infected Asian Patients in the SPRINT-1, SPRINT-2 and RESPOND-2 Trials. Hepatol International 2012; 6:164 (PP13-012).
99. Hu K-Q. Racial Difference in Response to Interferon/Ribavirin Therapy in Patients with Chronic Hepatitis C and Genotype 1 Infection. Invited lecture to the 14th International Symposium of Viral Hepatitis and Liver Disease, Shanghai, China. 2012, June 23.
100. Hu K-Q, Xu D, Xiaodong Li X, Liu Y. Different Clinical Presentation of HBeAg-positive (eAg+) Chronic Hepatitis B (CHB) in Patients with HBV Wild Type (WT), Pre-Core (PC) 1896 and/or Both Basal Core Promoter (BCP) 1762/1764 Mutant Infection. Hepatology 2012; 56 (SUPPL): 417A.
101. Wang C, Wang H, Xu D, Qu J, Yang Y, Hu K-Q. Associations of Hepatitis B Virus (HBV) Pre-Core (PC) and Basal Core Promoter (BCP) Mutations with the Risk of Hepatocellular Carcinoma (HCC). Hepatology 2012; 56 (SUPPL): 417A.
102. Nakai Y, Samarasena JB, Iwashita T, Park DH, Lee JG, Hu K-Q, et al. Autoimmune hepatitis diagnosed by endoscopic ultrasound-guided liver biopsy using a new 19-gauge histology needle. Endoscopy. 2012; 44 Suppl 2 UCTN:E67-8. Epub 2012/03/08. doi: 10.1055/s-0031-1291567. PubMed PMID: 22396285.
103. Kelvin Nguyen K, Calvin Q Pan CQ, Victor W Xia VW, Christine Liu C, Hu K-Q. Clinical Course and Outcomes of Asian Patients with Chronic Hepatitis B (CHB), Normal ALT, and Live Biopsy (LB) Report of Mild Liver Injury. Hepatology 2012; 56 (SUPPL): 416A.
104. Nguyen DL, Hu K-Q. Clinical Presentation of Autoimmune Hepatitis in Asian Americans: A Case Series Study. Poster presentation in 2013 ACG Meeting.
105. SG Lim, ML Yu , T Piratvisuth, K-Q Hu, F Poordad, JP Bronowicki, F Alvarez Bognar, W Deng, J Wahl, FA Helmond. Virological Response After 4-weeks Lead-in With Peginterferon/Ribavirin (PR) Predicts The Effectiveness of Adding Boceprevir to PR in Asian Treatment-Naïve Subjects: A Simulation Model Study Using Data from SPRINT-2. Poster presentation in 2013 APASL Meeting.
106. Pan CP, Zeng Z, Bae H, Trinh H, Ma X-L, Mi L-M, Leduc T-S, Chan S, K-Q Hu. Three-year outcomes of tenofovir disoproxil fumarate (TDF) treatment in Asian-American adults with chronic hepatitis B (CHB). Poster presentation in 2013 AASLD Meeting.
107. K-Q Hu. HBV Pre-C/BCP Mutations in Natural History of Chronic HBV Infection. An invited presentation. The 4th HBV Conference of Asian Pacific Association for the Study of the Liver. Guanzhou, China, 2014.
108. K-Q Hu. Alcohol and Hepatitis B and C. An invited presentation. The 24th Annual Conference of Asian Pacific Association for the Study of the Liver. Istanbul, Turkey.
109. Hu K-Q, Cui W. A highly specific and sensitive hepatitis C virus antigens enzyme immunoassay (HCV-Ags EIA) for one-step diagnosis of HCV infection. Hepatology 2015; 62 (suppl):251A (Oral presentation in 2015 AASLD meeting, San Francisco).
110. Hu K-Q, Cui W. Application of a novel hepatitis C virus antigens enzyme immunoassay (HCV-Ags EIA) for one-step diagnosis of active HCV infection using urine specimens. Hepatology 2015; 62 (suppl):1078A (Presidential poster presentation in 2015 AASLD meeting, San Francisco).
111. Hu K-Q, Cui W. Persistence of HCV-specific immune complexes in patients who cleared HCV infection spontaneously or achieved sustained virologic response to antiviral therapy. Hepatology 2015; 62 (suppl):712A (Poster presentation in 2015 AASLD meeting, San Francisco).
112. Pan CQ, Ouyang E, Tong MJ, Min A, Hu K-Q, Park J. Efficacy and Safety of Sofosbuvir-based Regimens in Asian-Americans With Chronic Hepatitis C Virus (HCV) Mono-Infection: A Multi-Center Study in the United States. Hepatology 2015; 62 (suppl):785A (Poster presentation in 2015 AASLD meeting, San Francisco).
113. K-Q Hu. Overview on HCV Antigen Tests and Its Potential for Clinical Application. 2017 APASL Annual Meeting, Shanghai, China
114. Zhang J, Huynh, T, K-Q Hu. Baseline Child-Pugh and MELD Scores Predict Sustained Normalization of Both AST and ALT in HCV-infected Patients Following DAA Induced SVR12. 2017 DDW, Chicago, IL.
115. Hu K-Q, Cui W. Undetectable Serum HCV Antigens after 12 Weeks of HCV DAA Treatment Predicts Sustained Virologic Response. 2017 DDW, Chicago, IL.
116. Hu K-Q, Cui W, Rouster SD, Sherman KE. Hepatitis C Virus Antigens Enzyme Immunoassay (HCV-Ags EIA) for One-step Diagnosis of Viremic HCV Co-infection in HIV Infected Individuals. 2017 DDW, Chicago, IL.
117. Pan C, Tiongson B, Hu K-Q, Han S-H, Tong, M, Chu D, Park J, et al. Real-World Study on Sofosbuvir-based Therapies in Asian American Patients with Chronic Hepatitis C. 2017 DDW, Chicago, IL.
118. Mittal M, Huynh T, and Hu K-Q. Dynamics and Characterization of DAA Treatment Induced Serum AFP Reduction in HCV-infected Patients without Hepatocellular Carcinoma (HCC). An oral presentation in 2017 AASLD, Washington DC.
119. Hu K-Q. Management of Ascites: US Experience. Annual Meeting of China Research Hospital Association for Liver Diseases, Jan 28, 218, Zhenjiang, China.
 
Book/Journal Forwards and Editorials
1. Hu K-Q. Book Foreword for “Hepatitis B, A Quiet Killer” by Rober J Peshek, DDS. International Foundation of Nutrition and Health, San Diego, CA. 2001.
2. Lu X-Y, Hu, K-Q. Forward for HBV special issue. J International Med Sci, 2005; 2:1.
3. Hu K-Q. Advances in managing hepatitis C virus (HCV) infection. International J Med Sci 2006; 3:28.
4. Hepatitis B Handbook (Chinese), Hu K-Q and Zhou Y (ed). Huasheng Publishing Company, 2008.
5. Hu K-Q and Pan C. Preface for the special issue “Advances in Diagnosing and Managing Hepatitis B Virus (HBV) Infection” North Am J Med Sci, 2011; 4:i.
6. Hu K-Q. Preface for Hepatobiliary Manifestations of Systemic Diseases. Clin Liver Dis 15 (2011) xiii-xiv.
7. Hu K-Q, Zhang Y-Y. Impact of Occult Hepatitis B Virus Infection or Hepatitis B Virus DNA Integration on Efficacy of Chronic Hepatitis C Treatment with Peginterferon and Ribavirin, Where Are We? J Clin Gastroenterol 2013;
8. Hu K-Q, Lau D. Preface for the special issue “Dawn of a New Era of Hepatitis C Management”. NAJMS 2014; 7(1):i.
9. Hu K-Q. Preface for the special issue Advances in some common chronic liver diseases. Front. Med. 2014, 8(2): 127–128.
10. Wang C, Hu K-Q, Yang Y. A reply to PMID 25284802. Hepatology 2015; 62(3):980-981.
 
Peer-Reviewed Original Articles
1. Hao LJ, Hu K-Q, Li FH. Indirect labeled avidin-biotin technique for detection of HBsAg in liver tissue and its comparison with PAP method. Acta Universitatis Medicinae Tongji 1986; 15:101-104.
2. Hao LJ, Hu K-Q, Li FH. Immunohistochemical study on several markers associated with hepatocellular carcinoma. Acta Universitatis Medicinae Tongji 1987; 16:38-41.
3. Hu K-Q, Song PH, Hao LJ. Immunohistochemical studies on hepatitis B markers in the liver tissue of patients with hepatocellular carcinoma. Inn Med 1987; 14:197-200.
4. Hu K-Q, Song PH, Hao LJ. A preliminary investigation on the relationship between expression of HBV antigens and liver cell necrosis. Chi J Pathol 1987; 16:86-89.
5. Hu K-Q, Yu ZQ, Li FH, et al. The clinical significance of HBV DNA and anti-HBc IgM in sera of patients with chronic liver disease. Chi J Inter Med 1988; 27:370.
6. Hu K-Q, Hao LJ, Will H. A preliminary study on localization of HBxAg in liver tissue of patients with chronic liver disease and its significance. Chi J Med 1988; 101:671-674.
7. Li FH, Hu K-Q, Yu ZQ, et al. The clinical significance of anti-HBc/IgA in the sera of patients with HBV infection. Shanghai J Immunol 1988; 8:177-180.
8. Li FH, Hu K-Q, et al. The preparation and application of PAP complexes containing multiple animal species. Shanghai J Immunol 1988; 8:300-302.
9. Yu ZQ, Li FH, Hu K-Q, et al. Serological detection of HBcAg by a Dot-ELISA and its clinical application. Shanghai J Immunol 1989; 9:27-31.
10. Zhang YY, Hu K-Q, Wang YK, et al. Immunohistochemical study on HDV infection in Chinese patients with chronic liver disease. Chi J Infect Dis 1989; 7:76-78.
11. Hu K-Q, Yu ZQ, Li FH, et al. Expression and clinical significance of pre-S1 and S2 proteins of HBV in sera of patients with chronic liver disease. Liver 1989; 9:146-152.
12. Hu K-Q, Hao LJ, Zhang YY, et al. Intrahepatic expression of pre-S1 and S2 proteins of hepatitis B virus and its possible relation to liver cell necrosis. Am J Gastroenterol 1989; 84:1538-1542.
13. Hu K-Q, Li FH, Yu ZQ, et al. The correlation of pre-S protein of HBV in between serum and liver in patients with chronic liver disease. Acta Universitatis Medicinae Tongji 1989; 18:222-224.
14. Hu K-Q, Yu ZQ, Hao LJ. A study of the binding ability of pre-S1 and S2 proteins of HBV to human serum albumin. Hepato-Gastroenterology 1990, 37: 338-341.
15. Lopez-Cabrera M, Letovsky J, Hu K-Q, Siddiqui A. Multiple liver-specific factors bind to the hepatitis B virus core/pregenomic promoter: transactivation and repression by CCAAT/enhancer binding protein. Proc Natl Acad Sci USA 1990; 87:5069-5073.
16. Hu K-Q, Vierling JM, Siddiqui A. Transactivation of HLA DR gene by hepatitis B virus X gene product. Proc Natl Acad Sci USA 1990; 87:7140-7144.
17. Hu K-Q, Siddiqui A. Regulation of the hepatitis B virus gene expression by the enhancer element I. Virology 1991; 181:721-726.
18. Lopez-Cabrera M, Letovsky J, Hu K-Q, Siddiqui A. Transcriptional factor C/EBP binds to and transactivates the enhancer element II. Virology 1991; 183:825-829.
19. Hu K-Q, Yu CH, Vierling JM. Direct detection of circulating hepatitis C virus RNA using probes from the 5' untranslated region. J Clin Invest 1992; 89:2040-2045.
20. Hu K-Q, Yu C-H, Vierling JM. Upregulation of ICAM-1 by the X protein product of the hepatitis B virus. Proc Nat Acad Sci (USA) 1992; 89:11441-11445.
21. Hu K-Q, Yu C-H, Vierling JM. One-step polymerase chain reaction for detection of hepatitis C virus RNA. Hepatology 1993; 18:270-274.
22. Hu K-Q, Yu CH, and Vierling JM. Simultaneous detection of both hepatitis B virus DNA and hepatitis C virus RNA using a combined one-step polymerase chain reaction technique. Hepatology 1995; 21: 901-907.
23.Villamil FG, Hu K-Q, Yu CH, Lee CH, Rojter SE, Podesta L, et al. Detection of hepatitis C virus with RNA polymerase chain reaction in fulminant hepatic failure. Hepatology 1995; 22:1379-1386.
24. Hu K-Q, Tong MJ. The long-term outcomes of patients with compensated HCV-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29:1311-1314.
25. Hu K-Q, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001; 96:1581-1586.
26. Hu K-Q, Yu C-H, Mineyama Y, et al. Inhibited proliferation of cyclooxygenase-2 (COX-2) expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor. International J Oncol, 2003 22:757-763.
27. Baron PW, Cantos K, Hillebrand DJ, Hu K-Q, Ojogho ON, Nehlsen-Cannarella S, Concepcion W. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 2003; 25:204-209.
28. Hill K, Hu K-Q, Cottrell A, Teichman S, Hillebrand DJ. Charcoal-based hemodiabsorption liver support for episodic type C hepatic encephalopathy. Am J Gastroenterol 2003; 98:2763-2770.
29. Hu K-Q, Kyulo N, Esrailian E, Thompson K, Chase R, Hillebrand DJ, Runyon BA. Overweight and Obesity, Hepatic Steatosis, and Progression of Chronic Hepatitis C: A Large Cohort Study in the United States. J Hepatol 2004; 40:147-154.
30. Hu K-Q, HY Yang, YS Lin, Lindsay KL, Redeker AG. The clinical profile of chronic hepatitis C in a major county medical center outpatient setting in the United States. Int J Med Sci 2004; 1:92-100.
31. Hu K-Q, Kyulo N, Lim, N, et al. Clinical Significance of Elevated Alpha Fetoprotein (AFP) in Patients with Chronic Hepatitis C, but Not Hepatocellular Carcinoma. Am J Gastroenterol 2004; 99:860-865.
32. Srikureja W, Kyulo NL, Runyon BA, Hu K-Q. MELD score is a better prognostic model than Child-Turcotte-Pugh score or discriminant function score in patients with alcoholic hepatitis. J Hepatol 2005; 42: 700-706.
33. Hu K-Q, Lee SM, Hu SX, Xia VW, Hillebrand DJ, Kyulo NL. Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function. Am J Gastroenterol 2005; 100:2010-2018.
34. Bini EJ, Brau N, Currie S, Shen H, Anand BS, Hu, K-Q, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. Veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005; 100:1772-1779.
35. Cui W, Yu C-H, Hu K-Q. In Vitro and In Vivo Effects and Mechanisms of Celecoxib-induced Growth Inhibition of Human HCC Cells. Clin Cancer Res 2005; 11:8213-8221.
36. Xing H, Wang S, Hu K-Q, Tao W, Li J, Gao Q, Yang X, Weng D, Lu Y, Ma D. Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy J Cancer Res Clin Oncol 2005:131:511-519.
37. Bräu N, Bini EJ, Currie S, Shen H, Schimidt WN, King PD, Hu, K-Q et al. Frequent dose reductions of interferon and ribavirin explain in part low sustained viral response rates in black patients with chronic hepatitis C genotype 1. J Viral Hepatitis 2006, 13, 242–249.
38. Xia VW, Du B, Braunfeld M, Neelakanta G, Hu K-Q, Nourmand H, Levin P, et al. Preoperative Characteristics and Intraoperative Transfusion and Vasopressor Requirements in Patients With Low Vs. High MELD Scores. Liver Transplant 2006; 12:614-620.
39. Xia VW, Du B, Tran A, Liu L, Hu K-Q, Jonathan R. Hiatt JR, et al. Intraoperative Hypokalemia in Pediatric Liver Transplantation: Incidence and Risk Factors. Pediatric Anesthesia 2006; 103:587-593.
40. Hillebrand HJ, Hill K, Hu K-Q. Cottrell A, Teichman. Formal heparin anticoagulation protocol improves safety of charcoal-based liver assist treatment. ASAIO J 2006; 52: 334-342.
41. Hu K-Q, Currie SL, Shen H, Cheung RC, Ho SB, Bini EJ, et al. Clinical Implications of Hepatic Steatosis in Patients with Chronic Hepatitis C: A Multicenter Study of U.S. Veterans. Dig Dis Sci 2007; 52; 570-578.
42. Esrailian E, Pantangco ER, Kyulo N, Hu K-Q, Runyon BA. Octreotide/midodrine therapy significantly improves survival in type 1 hepatorenal syndrome: analysis of 53 treated patients & 21 controls. Digest Dis Sci. 2007; 52:742-748.
43. Cui W, Hu SX, Tang Z, Hu K-Q. In vivo effects of cyclooxygenase-2 (COX-2) deletion on cellular signaling in HCC xenografts in nude mice. J Cancer Mol 2007; 3:49-54.
44. Xia VW, Ghobrial RM, Du B, Chen T, Hu K-Q, Hiatt JR, Busuttil RW, Steadman RH. Predictors of hyperkalemia in the prereperfusion, early postreperfusion, and late postreperfusion periods during adult liver transplantation. Anesth Analg 2007;105:780-785.
45. Xia VW, Hu KQ, Hiatt JR, Busuttil RW, Steadman RH. Predictors of postreperfusion hyperkalemia in adult liver transplantation: The impact of donors. Liver Transplantation 2007; 13: S163-S163.
46. Lah J, Cui W, Hu K-Q. Inhibitory effects and mechanisms of silibinin on growth of human hepatoma cell lines. World J Gastroenterol 2007 13(40): 5299-5305.
47. Marcellin P, Heathcote EJ, Buti M, et al (Hu K-Q was listed in appendix as a study participanat). Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008 Dec 4; 359:2442-55.
48. Cui W, Hu SX, Tang Z-Y, Hu K-Q. In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice. Anti-Cancer Drugs 2008, 19:891–897.
49. Cheung RC, Currie WS, Shen H, Bini EJ, Ho SB, Bhupinderjit J, Anand S, Hu K-Q, Wright TL, MD, Morgan TR, et al. Can We Predict the Degree of Fibrosis in Chronic Hepatitis C Patients Using Routine Blood Tests in Our Daily Practice? J Clin Gastroenterol 2008;42:827–834.
50. Park C, Hsu C, Neelakanta G, Nourmand H, Braunfled M, Wray C, Steadman R, Hu, K-Q, Cheng R, and Xia V. Severe Intraoperative Hyperglycemia Is Independently Associated with Surgical Site Infection after Liver Transplantation. Transplantation 2009; 87:1031-1036
51. Cui W, Gu F, Hu K-Q. Effects and mechanisms of silibinin on human Hepatocellular carcinoma xenografts in nude mice. World J Gastroenterol 2009; 15(16): 1943-1950.
52. Xia V, Obaidi R, Park C, Braunfeld M, Neelakanta G, Nourmand H, Hu K-Q, and Steadman R. Insulin Therapy in Divided Doses Coupled with Blood Transfusion versus Large Bolus in Patients at High Risk for Hyperkalemia during Liver Transplantation. J Cardioth Vasc Anesth in press
53. Hu SX, Kyulo NL, Xia VW, MD, Hillebrand DJ, Hu K-Q. Factors Associated with Hepatic Fibrosis in Patients with Chronic Hepatitis C: A Retrospective Study of a Large Cohort of US Patients. J Clin Gastroeterol 2009; 43: 758–764.
54. MCHUTCHISON JG, LAWITZ EJ, SHIFFMAN ML, ET AL (Hu K-Q was listed in appendix as a study participant). PEGINTERFERON ALFA-2B OR ALFA-2A WITH RIBAVIRIN FOR TREATMENT OF HEPATITIS C INFECTION. N ENGL J MED 2009; 361:580-93.
55. Mellen JS, Xia VW, Hashemzadeh M, Imagawa D, Jamal M, Hoefs J, Hu K-Q. The clinical presentation of chronic hepatitis B virus (HBV) infection in Asian Americans: A single center retrospective study. J Clin Gastroeterol 2010; 44:364-370.
56. Cui W, Chen SL, Hu K-Q. Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. Am J Transl Res 2010; 2:95-104.
57. Hu K-Q, Schiff ER, Kowdley KV, Min AD, Shiffman ML, Lee WM, Goodman ZD, et al. Histologic evidence of active liver injury in chronic hepatitis B patients with normal range or minimally elevated alanine aminotransferase levels. J Clin Gastroeterol 2010; 44:510-516.
58. Xia V, Obaidi R, Park C, Braunfeld M, Neelakanta G, Nourmand H, Hu K-Q, and Steadman R. Insulin Therapy in Divided Doses Coupled with Blood Transfusion versus Large Bolus in Patients at High Risk for Hyperkalemia during Liver Transplantation. J Cardioth Vasc Anesth 2010; 24:80-83.
59. Park C, Huh M, Steadman R, Cheng R, Hu K-Q, Farmer D, Hong J, Duffy J, Busuttil R, and Xia V. Extended Criteria Donor and Severe Intraoperative Glucose Variability: Association with Surgical Reoperation for Hemorrhage in Liver Transplantation. Transpl Proc 2010; 42:1738-1740.
60. Sulkowski MS, Shiffman ML, Afdhal NH, et al (Hu K-Q was listed in appendix as a study participant). Hepatitis c virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010; 139:1602-1611.
61. Harrison SA, Rossaro L, Hu K-Q, et al. Serum cholesterol and statin use predict virologica response to peginterferon and ribavirin therapy. Hepatology 2010; 52:864-874.
62. Hu K-Q Freilich B, Brown RS, Brass C, Jacobson IM. Impact of Hispanic or Asian Ethnicity on the Treatment Results From the WIN-R Trial. J Clin Gastroenterol 2011;00:000–000
63. Muir AJ, Hu K-Q, Gordon SC, et al. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J Viral Hepatitis. 2010 Nov 25. doi: 10.1111/j.1365-2893.2010.01402.x. [Epub ahead of print].
64. Wong PY, Xia VW, Imagawa DK, Hoefs J, Hu K-Q. Clinical presentation of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian-Americans. J immigrant minority health. 2010; doi 10.1007/s10903-010-9395-8.
65. Chen J, Singhapricha T, Hu -Q, et al. Post-liver transplant acute renal injury by the RIFLE criteria in patients with normal pretransplant serum creatinine concentrations: a matched study. Transplantation 2011; 91:348-353.
66. Pan C.Q., Hu K-Q., Yu A. S., Chen W., Bunchorntavakul C., Reddy K. R. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. Journal of Viral Hepatitis, 2012, 19, 213–219.
67. Chen J, Singhapricha T, Memarzadeh M, Ziman A, Yuan S, Hu K-Q, Steadman RH, Busuttil RW, Xia VW. Storage age of transfused red blood cells during liver transplantation and its intraoperative and postoperative effects. World J Surg. 2012 Oct; 36(10):2436-42. doi: 10.1007/s00268-012-1691-0. PMID: 22714578.
68. Pan CQ, Tong M, Kowdley KV, Hu K-Q, Chang TT, Lai CL, Yoon SK, Lee SS, Cohen D, Tang H, Tsai N. High rates of viral suppression after long-term entecavir treatment of Asian patients with hepatitis B e antigen-positive chronic hepatitis B. Clin Gastroenterol Hepatol. 2012 Sep;10(9):1047-1050.e1. doi: 10.1016/j.cgh.2012.03.016. PMID: 22475742.
69. Tong MJ, Kowdley KV, Pan C, Hu K-Q, Chang TT, Han KH, Yoon SK, Goodman ZD, Beebe S, Iloeje U, Tang H. Improvement in liver histology among Asian patients with chronic hepatitis B after long-term treatment with entecavir. Liver Int. 2013 Apr;33(4):650-1. doi: 10.1111/liv.12121. PMID: 23489906.
70. Yang YP, Qu JH, Chang XJ, Lu YY, Bai WL, Dong Z, Wang H, An LJ, Xu ZX, Wang CP, Zeng Z, Hu K-Q. High intratumoral metastasis-associated in colon cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced hepatocellular carcinoma. J Transl Med. 2013 Feb 15;11:41. doi: 10.1186/1479-5876-11-41. PMID: 23414367.
71. Gordon SC1, Reddy KR, Jacobson IM, Poordad F, Bronowicki JP, Bacon B, Buti M, Hu KQ, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Lawitz EJ. Boceprevir plus peginterferon a-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response. J Clin Gastroenterol. 2014 May-Jun; 48(5):435-43. doi: 10.1097.
72. Hsu Y-N, Pan CQ, Abbasi A, Xia VW, Bansal R, Hu K-Q. Clinical Presentation and Disease Phases of Chronic Hepatitis B Using Conventional Verses Modified ALT Criteria in Asian Americans. Digest Dis Sci 2014; 59(4): 865-871.
73. Nguyen K, Nguyen T, Shen D, Tran D, Banh K, Ruan V, and Hu K-Q. Prevalence and Presentation of Hepatitis B and C Virus (HBV and HCV) Infection in Vietnamese Americans via Serial Community Serologic Testing. J Immigrant Minority Health. 2015; 17:13–20.
74. Rong G, Bai W, Dong Z, Wang C, Lu Y, Zeng Z, et al. Long-Term Outcomes of Percutaneous Cryoablation for Patients with Hepatocellular Carcinoma within Milan Criteria. PloS One. 2015;10(4):e0123065. Epub 2015/04/08. doi: 10.1371/journal.pone.0123065. PubMed PMID: 25849963; PubMed Central PMCID: PMCPMC4388736.
75. Wang C, Wang H, Yang W, Hu K, Xie H, Hu K-Q, Bai W, Dong Z, Lu Y, Zeng Z, Lou M, Wang H, Gao X, Chang X, An L, Qu J, Li J, Yang Y. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology. 2015 61:1579-90.
76. Morgan TR, Osann K, Bottiglieri T, Pimstone N, Hoefs JC, Hu K-Q, Hassanein T, Boyer TD, Kong L, Chen WP, Richmond E, Gonzalez R, Rodriguez LM, Meyskens FL. A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum a-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP. Cancer Prev Res (Phila). 2015; 8(9):864-72. doi: 10.1158/1940-6207.
77. Nguyen K, Pan C, Xia V, Hu J, Hu K-Q. Clinical course of chronic hepatitis B (CHB) presented with normal ALT in Asian American patients. J Viral Hepat. 2015 Oct; 22(10):809-16. doi: 10.1111/jvh.12388.
78. Hu K-Q, Cui W. A highly specific and sensitive hepatitis C virus antigens enzyme immunoassay (HCV-Ags EIA) for one-step diagnosis of HCV infection. Hepatology 2016; 64:415-424.
79. Wang C, Wang C, Jia ZF, Wu X, Wen SM, Kong F, Hu K-Q, Li J, Jiang J, Niu JQ. Protective effect of an improved immunization practice of mother-to-infant transmission of hepatitis B virus and risk factors associated with immunoprophylaxis failure. Medicine 2016; 95:34. e4390. doi: 10.1097/MD.0000000000004390
80. Huang JY, Samarasena JB, Tsujino T, Lee J, Hu K-Q, McLaren CE, Chen WP, Chang KJ. EUS-guided portal pressure gradient measurement with a simple novel device: a human pilot study. Gastrointest Endosc. 2017; 85:996-1001.
81. Hu K-Q, Cui W.Persistence of Circulating Hepatitis C Virus Antigens-Specific Immune Complexes in Patients with Resolved HCV Infection. Digestive Diseases and Sciences 2018; 63:1237–1242.
82. Pan CQ, Tiongson BC, Hu K-Q, Han SB, Tong M, Chu D, Park J, Lee TP, Bhamidimarri KR, Ma X, Xiao PY, Mohanty SR, Wang D.. Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C. J Clin Gastroenterol. 2018 Jun 16. doi: 10.1097/MCG.0000000000001078.
 
Review Articles and Chapters
1. Hu K-Q. Avidin-biotin immunoassays and the application in studying infectious diseases. Overseas Med Sect Infect Dis 1985; 12:100-104.
2. Hu K-Q. The advances in the molecular virology of hepadna viruses. Overseas Med ReSect Infect Dis 1986; 13:244-248.
3. Hu K-Q. Pre-S/S and Pre-core proteins of hepatitis B virus and their implication. Overseas Med Sect Infect Dis 1987; 14:51-55.
4. Hu K-Q. The advances in molecular regulation of hepatitis B viral gene expression. Overseas Med Sect Infect Dis 1988; 15:254-257.
5. Hu K-Q. The molecular virology and pathogenesis of human immunodeficiency virus. Overseas Med Sect Infect Dis 1989; 16:56-60.
6. Hu K-Q. Recent advances in hepatitis C virus research. Overseas Med Sect Infect Dis 1989; 16:56-60.
7. Vierling JM and Hu K-Q. Immunologic Mechanisms of Injury. In: Liver and Biliary Diseases. Kaplowitz N (ed). Williams and Wilkins, pp 48-69, 1991.
8. Jameel S, Siddiqui A and Hu K-Q. Molecular Biology of Hepatitis Viruses. In: Principles and Practice of Gastroenterology and Hepatology (2nd Ed), Gitnick G (Ed). Appleton & Lange Paramount Publishing, Norwalk, Connecticut. Pp 743-757, 1994.
9. Hu K-Q and Vierling JM. Molecular diagnosis for the viral hepatitis infection. Gastroenterology Clin N Am. 1994; 23:479-498.
10. Freilich BL, Hu K-Q and Vierling JM. Immunopathogenesis of Autoimmune Hepatobiliary Diseases. Curr Opin Gastroenterology, 1994; 10:257-268.
11. Freilich BL, Hu K-Q and Vierling JM. Role of the immune response in viral hepatitis, hepatocellular carcinoma and alcoholic hepatitis. Curr Opin Gastroenterology 1994; 10:269-276.
12. Song PH and Hu K-Q. Hepatitis B Virus and Chronic Hepatitis B. In: Hepatology. Liang GH (Ed). People's Health Publication House, Beijing, pp 496-526, 1995 (in Chinese).
13. Hu K-Q, YU CH, Kuhns M and Vierling JM. Detection of Serum Hepatitis C Virus RNA by Slot Hybridization Using Probes from the 5’ Untranslated Region. In: PCR: Protocol for Diagnosis of Human and Animals Virus Diseases. Becker Y and Darai G (eds). Springer-Verlag, Heidelberg, Germany. pp 99-105, 1995.
14. Vierling JM and Hu K-Q. Immunologic Mechanisms of Hepatobiliary Injury. In: Liver and Biliary Diseases. Second Edition. Kaplowitz N (ed). Williams and Wilkins, Baltimore, MD, pp 55-87, 1996.
15. Hu K-Q, Runyon BA. Use of prescription and nonprescription drugs, and herbal medicines in patients with cirrhosis. 2000, Yourdoctor.com.
16. Hu K-Q. Molecular analysis and clinical implication of “occult” HBV infection. J Gastroenterol and Hepatology. 2000; 15 (Suppl): 192.
17. Hu K-Q, Vierling JM, Redeker A. Viral, host, and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepatitis 2001; 8: 1-18.
18. Yu AS, Hu K-Q. Management of Ascites. Clinics in Liver Dis 2001; 5: 541-568.
19. Hu K-Q, AS Yu, BA Runyon. Treatment of Patients with Cirrhosis and Ascites. In: basic Principles of Gastroenterology for Primary Care Physicians. Montoro MA, et al., (2nd ed). Almirall Prodesfarma, Barcelona. pp 621-634, 2002 (in Spanish).
20. Hu K-Q. Occult HBV infection and its clinical implications. J Viral Hepatitis 2002; 9:245-254.
21. Hu K-Q. Rationale and feasibility of chemoprevention of hepatocellular carcinoma by cyclooxygenase 2 (COX-2) inhibitors. J Lab Clin Med 2002; 139:234-243.
22. Song PH and Hu K-Q. Hepatitis B Virus and Chronic Hepatitis B. In: Hepatology. Liang GH (2nd Ed). People's Health Publication House, Beijing. pp 633-664, 2003 (in Chinese).
23. Hu K-Q. Cyclooxygenase 2 (COX2)-prostanoid pathway and liver diseases. Prostaglandins Leukotrienes and Essential Fatty Acids. 2003; 69:329-337.
24. Hu K-Q. Immunoparhogenesis of Viral Hepatitis. In: Clinical Hepatology. Yao, KB (ed). Shanghai scientific and technology publisher, Shanghai, pp 89-97, 2004 (in Chinese).
25.Yao KB, Hu K-Q. Hemochromatosis. In: Clinical Hepatology. Yao, KB (ed). Shanghai scientific and technology publisher, Shanghai, pp 596-609, 2004 (in Chinese).
26. Hu K-Q, Yao KB. The Porphyrias. In: Clinical Hepatology. Yao, KB (ed). Shanghai scientific and technology publisher, Shanghai, pp 613-618, 2004 (in Chinese).
27. Hu K-Q, Runyon BA. Ascites and Spontaneous Bacterial Peritonitis. In: Handbook of Liver Disease, Friedman LS, Keeffe EB (2nd eds). Churchill Livingstone, Philadephia, pp 149-163, 2004
28. Hu K-Q, Runyon BA. Ascites and Its Complication. In: Advanced Therapy in Gastroenterology and Liver Diseases, 5th eds, by Bayless TM and Diehl AM. B.C. Decker Inc., Hamilton, London, pp 656-660, 2005
29. Hu K-Q. A practical approach to management of chronic hepatitis B. International J Med Sci 2005; 2:27-35.
30. Yoon EJ, Hu K-Q. Hepatitis C Virus (HCV) Infection and Hepatic Steatosis. International J Med Sci 2006; 3:53-56.
31. Huang RH, Hu K-Q. A Practical Approach to Managing Patients with HCV Infection. International J Med Sci 2006; 3; 63-68.
32. Whang CS, Hu K-Q. Hepatitis C in Chronic Kidney Disease Patients: Course and Management. Current Hepatitis Report. 2007; 6:96-102.
33.Hu K-Q. Treatment of Chronic Hepatitis B (CHB): Mastering the Basics on a Complex Topic. Adv Stud Med 2007; 7:482-490.
34. Hu K-Q. Hepatitis B Virus (HBV) Infection in Asian and Pacific Islander Americans (APIAs): How Can We Do Better for this Special Population? Am J Gastroenterol 2008; 103: 1824-1833.
35.Pan C, Jia JD, Chu C-J, Hou JL, Hu K-Q. Epidemiology, Presentation, and Treatment of Chronic HBV Infection in Mainland China, in Taiwan, and in Chinese Americans in the United States. Current Hepatitis B Reports 2008, 2:159–165.
36. Hu K-Q. Update on Treatment of Chronic Hepatitis B (CHB). North Am J Med Sci, 2009; 2:84-87.
37. Hu K-Q. Medical Diseases Related to Biliary Surgery. In: Biliary Surgery. Zou S (ed). People’s Medical Publishing House, Beijing, pp 781-786, 2010.
38. Hu K-Q. Vanishing Bile Duct syndrome. In: Biliary Surgery. Zou S (ed). People’s Medical Publishing House, Beijing, pp 813-816, 2010.
39. Samarasena JB, MD and Hu K-Q. Hepatobiliary Manifestations of Gastrointestinal and Nutritional Disorders. Cli Liv Dis 2011.
40. Hu K-Q. The Impact of HBV Infection and Barriers to HBV-related Care in Asian Americans. North Am J Med Sci, 2011; 4:14-17.
41. Kong X, Li M, Hu K-Q. Update on the Recommended HBV Screening in the United States. North Am J Med Sci, 2011; 4:18-22.
42.Pan C and Hu K-Q. Management of Initial HBV Therapy for an HBeAg-Negative Patient: A Case Discussion. North Am J Med Sci, 2011; 4:50-56.
43. Hu K-Q, Pan CQ Goodwin D. Barriers to Screening for Hepatitis B Virus Infection in Asian Americans. Dig Dis Sci DOI 10.1007/s10620-011-1840-6.
44. Hu K-Q. Chapter 34. Hepatitis C. In: Cut Instincts, A Clinician’s Handbook of Digestive and Liver Diseases, Esrailian E (1st ed). CLACK Incorporated, Thorofare, pp 237-244, 2012.
45. Hu K-Q, Avanesyan, A, Runyon BA. Chapter 11. Ascites and Spontaneous Bacterial Peritonitis. In: Handbook of Liver Disease, Friedman LS, Keeffe EB, Dienstag JL (3rd eds). Elsevier Saundes, Philadephia, pp 159-172, 2011.
46. Hu K-Q, Pan CQ, Goodwin D. Barriers to Screening for Hepatitis B Virus Infection in Asian Americans. Dig Dis Sci 2011; DOI 10.1007/s10620-011-1840-6.
47. Chao DC, Hu K-Q. Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B. Drug design, Development and Therapy 2013 dx.doi.org/10.2147/DDDT.S33947.
48. Pan CQ, Hu KQ, Tsai N. Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients. Antivir Ther. 2013; 18(7):841-52.
49. Hu K-Q, Sun J, Ding HF, Song PH. Hepatitis B Virus and Chronic Hepatitis B. In: Hepatology. Wang JL, Li SB (3rd Ed). People's Health Publication House, Beijing, pp 498-515, 2013 (in Chinese).
50. Yang DF, Tian DY, Hu K-Q. Hepatitis C Virus and Hepatitis C. In: Hepatology. Wang JL, Li SB (3rd Ed). People's Health Publication House, Beijing, pp 515-533, 2013 (in Chinese).
51. Nguyen DL, Hu K-Q. Clinical Monitoring of Chronic Hepatitis C Based on its Natural History and Therapy. NAJMS 2014; 7(1):21-27.
52. Skupsky J and Hu K-Q. Current hepatitis B treatment guidelines and future research directions. Front. Med. 2014; 8(2): 145-157.
53. Zhang Y-Y, Hu K-Q, Duan ZP. New perspective on the natural course of chronic HBV infection. Front. Med. 2014, 8(2): 129–134.
54. Hu K-Q. Advances in Clinical Application of Cryoablation Therapy for Hepatocellular Carcinoma and Metastatic Liver Tumor. J Clin Gastroenterol 2014; 48:830-836.
55. Zhang Y-Y, Hu K-Q. Rethinking the pathogenesis of hepatitis B virus (HBV) infection. J Med Virol 2015; doi.org/10.1002/jmv.24270
56. Zhang J, Gao S, Duan ZP, Hu K-Q. Overview on acute-on-chronic liver failure. Front. Med., 2016, 10(1): 1-17.
57. Zhang J, Nguyen D, and Hu K-Q. Chronic Hepatitis C Virus Infection: A Review of Current Direct-Acting Antiviral Treatment Strategies. NA J Med Sci. 2016; 9:47-54.
58. Guo Z, Yu Z, Hu K-Q. Overview on Current Management of Hepatic Encephalopathy. N A J Med Sci. 2016; 9:59-65.
59. Mittal M, Hu K-Q. Clinical Implications and Management of Chronic Occult Hepatitis B Virus Infection. Curr Hepatology Rep 2017; 16:90-96.
60. Tong MJ, Pan CQ, Han S-H, Lu D S-K, Raman S, Hu K-Q, Lim JK, Hann AD, Min AD. An expert consensus for the management of chronic hepatitis B in Asian Americans. Alimentary Pharmocology & Therapeutics. 2018; DOI: 10.1111/apt.14577
Professional Society
Member of the American Assoc. for the Study of Liver Disease
Other Experience
Guest Professor
Tongji Medical College, Huazhoung University of Science and Technology 2000—pres

Research Center
UCI Chao Comprehensive Cancer Center
Last updated
12/05/2018